Why the study?
Do rhesus rotavirus or RIT 4237 bovine rotavirus vaccines prevent rotavirus diarrhea in Navajo infants?
Do rhesus rotavirus or RIT 4237 bovine rotavirus vaccines prevent rotavirus diarrhea in Navajo infants?
Neither the rhesus rotavirus vaccine nor the RIT 4237 bovine rotavirus vaccine demonstrated efficacy in preventing rotavirus diarrhea in a Navajo infant population.
This is the authors' abstract. We don't add key points for this paper.
A double-blind, randomized, placebo-controlled trial was conducted to evaluate the safety and efficacy of a rhesus rotavirus vaccine and RIT 4237, a bovine rotavirus vaccine, in a Navajo population. Infants aged 2-5 months were randomized to receive one dose of either 10(4) pfu of the rhesus rotavirus vaccine or 10(8) pfu of the RIT 4237 vaccine or placebo. Eleven (10.2%) of 108 infants in the rhesus vaccine group, 11 (10.4%) of 106 in the RIT 4237 group, and 9 (8.4%) of 107 in the placebo group experienced rotavirus diarrhea during the follow-up period of 17 months. Thus, in this population, neither vaccine was efficacious in preventing rotavirus diarrhea.
Answers are grounded in this paper and cite their sources.
Neither vaccine prevents rotavirus diarrhea in Navajo infants; challenges efficacy assumptions and directs research to alternative candidates or populations.
No takes yet. Share an insight, caveat, or question.
Santosham et al. (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: